Latest news
Regulatory Clarity and Trial Progress Support Azenosertib Outlook; Buy Rating Reiterated with Unchanged $10 Price Target - tipranks.comtipranks.com · Fri, 07 Aug 2026 16:05:56 GMTPhil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales - tipranks.comtipranks.com · Tue, 04 Aug 2026 07:00:00 GMT